Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma

Konstas, Anastasios G. P.; Holló, Gábor

doi:10.1080/14656566.2016.1182983

Cited by 17 publications

(12 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of this open-label, multicenter observational study confirm earlier results that the preservative-free fixed combination tafluprost/timolol provides an effective IOP control in patients who are inadequately controlled on monotherapy, in patients with high baseline IOP levels and in patients who are sensitive to preservatives 7–10,20. Usually fixed combinations are used in patients inadequately managed on monotherapy or in patients with multiple treatment regimens to reduce the number of applications and thus to reduce the complexity of medical treatment 1,25,26.…”

Section: Discussionsupporting

confidence: 84%

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

Pillunat

Erb²,

Ropo

et al. 2017

OPTH

View full text Add to dashboard Cite

BackgroundEfficacy, tolerability and safety of the novel preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% (Taptiqom®) were investigated in an observational study in Germany.ObjectiveTo assess efficacy, tolerability and safety of the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% in a real-life setting.MethodsIntraocular pressure (IOP) was recorded for each eye at baseline (any previous therapy or untreated) and 4–16 weeks after changing medical treatment to or initiating treatment with the preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5%. Change in IOP was evaluated over the study period for all patients and for specific pretreatment subgroups. Clinical signs such as conjunctival hyperemia and lid-parallel conjunctival folds (LIPCOF) were recorded using standardized comparative photographs. Corneal staining, subjective symptoms and local comfort were measured using a four-step scale. All adverse events were recorded.ResultsAmong 1,157 patients enrolled, 1,075 patients were treated with the preservative-free fixed combination as the only medication at the final visit. Medical treatment was initiated in 741 patients because of an insufficient IOP-lowering effect of the prior medication. In 343 patients, medication was changed because of tolerability issues. The preservative-free fixed combination lowered IOP significantly in the subgroup of naïve patients, all subgroups with prior monotherapy and patients with prior fixed combinations: naïve patients: −8.9 mmHg, alpha- 2-agonists: −6.4 mmHg, beta-blockers: −5.7 mmHg, carbonic anhydrase inhibitors: −5.2 mmHg, prostaglandins: −4.7 mmHg, fixed-combination prostaglandins/timolol: −2.4 mmHg. At the final visit, clinical signs and subjective symptoms were improved in patients with prior medical therapy. Local comfort was rated as “very good” or “good” by 89.1% of patients at the final visit. Only few adverse events occurred during the treatment period.ConclusionThe preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% was effective, well tolerated and showed a good safety profile.

show abstract

Section: Discussionsupporting

confidence: 84%

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

Pillunat

Erb²,

Ropo

et al. 2017

OPTH

View full text Add to dashboard Cite

show abstract

“…The mean relative reduction in IOP was 46% in the experimental arm versus nearly 27% in the conventional arm. In other words, in the present study, the initial target IOP level recommended for early to moderate glaucoma was already reached by mono‐therapy, whereas the advanced stage recommendation was only fulfilled in the multi‐therapy arm (Konstas & Hollo 2016). …”

Section: Discussionmentioning

confidence: 53%

Initial intraocular pressure reduction by mono‐ versus multi‐therapy in patients with open‐angle glaucoma: results from the Glaucoma Intensive Treatment Study

Lindén

Heijl

Jóhannesson

et al. 2018

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo study newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differences in initial intraocular pressure (IOP) reduction, target IOP levels reached and influence of untreated baseline IOP on IOP reduction.MethodsPatients newly diagnosed with manifest primary open‐angle glaucoma and included in the Glaucoma Intensive Treatment Study (GITS) were randomized to immediate intensive treatment with any of three different IOP‐lowering substances supplied in two bottles plus 360° laser trabeculoplasty or to conventional stepwise treatment starting with a single‐drug. Intraocular pressure reduction was analysed 1 month after initiation of treatment.ResultsOne hundred eighteen patients (143 eyes) received mono‐therapy and 122 patients (152 eyes) multi‐therapy. Median baseline IOP was 24.0 (min: 9.7, max: 56.0) mmHg in mono‐therapy eyes and 24.0 (min: 12.3, max: 48.5) mmHg in multi‐therapy eyes (p = 0.56). After 1 month in the two groups, respectively, values for median IOP reduction were 6.3 (range: −5.3–31.0) and 11.0 (range: 0.7–34.5) mmHg, and for mean relative decline 26.8 (range: −32.0–55.4) and 46.0 (range: 4.6–81.6) % (p = 0.000). A larger proportion of the multi‐therapy patients reached each target IOP level (p = 0.000). The higher the baseline IOP, the larger the observed pressure reduction, considering both absolute and relative figures. The effect was more pronounced in eyes with multi‐therapy than in those with mono‐therapy (p = 0.000). For every mmHg higher IOP at baseline, the IOP was reduced by an additional 0.56 (mono‐therapy) or 0.84 (multi‐therapy) mmHg.ConclusionIntensive treatment led to considerably greater IOP reduction than mono‐therapy. Among patients with IOP ≥30 mmHg at diagnosis an IOP of <16 was reached in 2/3 of those with multi‐therapy but in none with mono‐therapy. The IOP reduction was highly dependent on the untreated IOP level.

show abstract

“…Являясь фторированным АП F2α, или эфиром тафлупростовой кислоты, препарат обладает выраженными свойствами селективного агониста FP-рецепторов человека, превосходящими таковые у других АП, в частности у латанопроста [1]. Фиксированная комбинация (ФК) тафлупроста с тимололомтафлупрост/тимолол -содержит 15 мг/мл тафлупроста и 5 мг/мл тимолола малеата [2]. Следует отметить, что это одна из первых ФК АП с тимололом, не содержащая консервантов [2].…”

Section: актуальность проблемыunclassified

“…Фиксированная комбинация (ФК) тафлупроста с тимололомтафлупрост/тимолол -содержит 15 мг/мл тафлупроста и 5 мг/мл тимолола малеата [2]. Следует отметить, что это одна из первых ФК АП с тимололом, не содержащая консервантов [2]. Перспективность применения фиксированных комбинаций АП с тимололом с целью более выраженного снижения ВГД неоднократно обсуждалась в литературе [3].…”

Section: актуальность проблемыunclassified

Effect of Tafluprost and Tafloprost/Timolol on the Optic Nerve Head, Peripapillary and Macular Microcirculation According to OCT-Angiography

Курышева¹,

Arzhukhanov²,

Tkhamadokova³

2018

Ophthalmology in Russia

View full text Add to dashboard Cite

Relevance. The ability of antiglaucoma drugs to improve ocular hemoperfusion is an important aspect of their action. Tafluprost is the first prostaglandin analogue (PA) containing no preservatives. The efficacy and safety of tafluprost, as well as tafluprost/timolol fixed combination (FC), was demonstrated in randomized multicenter trials. However, there is no literature on the effect of tafluprost and it’s FC on peripapillary and macular blood flow.Purpose. to assess the effect of tafluprost and tafloprost/timolol on the microcirculation in the optic nerve head, peripapillary area and macula in patients with primary open-angle glaucoma (POAG) according to OCT angiography (OCT-A).Patients and methods. OCT-A was performed in dynamics with an interval of a week in 36 patients (36 eyes) with a newly diagnosed initial stage of POAG, 12 received tafluprost, 12 — tafluprost/timolol FCs, 12 eyes represented control group (no drugs were prescribed). The change in IOP, mean perfusion pressure (PP) of the eye, and vessel density (VD) inside the optic nerve head (ONH) (inside disc), as well as in the peripapillary retina and macula were evaluated by comparing paired repeated observations using the median growth analysis.Results. In the tafluprost group there was a decrease in IOP by 19.4 % and an increase in PP by 8.7 % from the reference level. In the tafluprost/timolol group, these figures were 43 % and 30.1 %, respectively. OCT-A values did not change reliably, except for VD inside Disc: in the tafluprost group, the median growth was –2.28 (p = 0.02), for the tafluprost/ timolol group — –1.82 (p = 0.03). These changes were obtained in 11 patients of 12 in each group under treatment. In patients who did not receive treatment, all indicators remained unchanged.Conclusions. The results of this study showed a decrease in the density of the microcirculatory bed in the ONH in patients with initial glaucoma against the background of the tafluprost and tafluprost/timolol treatment, which can be explained by the restoration of autoregulation of the ocular blood flow in conditions of pronounced hypotensive drugs effect.

show abstract

Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma

Cited by 17 publications

References 89 publications

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study

Initial intraocular pressure reduction by mono‐ versus multi‐therapy in patients with open‐angle glaucoma: results from the Glaucoma Intensive Treatment Study

Effect of Tafluprost and Tafloprost/Timolol on the Optic Nerve Head, Peripapillary and Macular Microcirculation According to OCT-Angiography

Contact Info

Product

Resources

About